Monopar Therapeutics Inc ( (MNPR) ) has issued an announcement.
On May 7, 2025, Monopar Therapeutics Inc. presented data on the long-term efficacy and safety of its drug candidate ALXN1840 for Wilson disease at the EASL International Liver Congress 2025. The data, pooled from several clinical trials, highlighted sustained improvements in patient symptoms, increased copper mobilization, and higher patient-reported convenience compared to standard care, with fewer than 5% of patients experiencing serious adverse events. This presentation underscores ALXN1840’s potential as a therapeutic option for Wilson disease, potentially impacting the company’s market positioning and offering significant benefits to patients.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.
To see Spark’s full report on MNPR stock, click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. The company is working on late-stage ALXN1840 for Wilson disease and has radiopharmaceutical programs for imaging and treating advanced cancers.
Average Trading Volume: 32,260
Technical Sentiment Signal: Buy
Current Market Cap: $237M
Learn more about MNPR stock on TipRanks’ Stock Analysis page.